Microbial or mammalian? BioSilta backs the former licensing E. Coli platform
Microbial expression systems are cheaper and more efficient than mammalian cell cultures says BioSilta which has acquired the rights to an E. coli based platform.
Archives for April 7, 2016
Eppendorf addressing stem cell scale-up challenges in Horizon 2020 project
Eppendorf will tackle the challenges of scaling-up human induced pluripotent stem cells (hiPSCs) as part of a Horizon 2020 project to develop cell-based heart therapies.
Asymptote to commercialize in clinic cell therapy thawing tech
Asymptote plans to launch a point-of-care thawing system for cell therapies it developed with Cell and Gene Therapy Catapult (CGTC).